Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Different expressed genes beween osimertinib-treated and control group

ABSTRACT: Different expressed genes beween osimertinib-treated and control group

PROVIDER: PRJNA1137072 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29870805_1.fastq.gz	Fastqsanger.gz
	SRR29870805_2.fastq.gz	Fastqsanger.gz
	SRR29870806_1.fastq.gz	Fastqsanger.gz
	SRR29870806_2.fastq.gz	Fastqsanger.gz
	SRR29870807_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Different expressed genes beween osimertinib-treated and control group

Project description:Mice treated with osimertinib appeared skin problems. By comparing osimertinib group and control group, mechanisms were identified.

2024-12-31 | GSE272508 | GEO

scRNAseq of EGFR-mut PC9 cells control or treated for 24h or 72h with osimertinib

Project description:The experiment investigates transcriptional reponse of EGFR-mut PC9 lung cancer cells following treatment for 24h or 72h with EGFR-inhibitor osimertinib compared to control cells on a single cell level.

2021-07-19 | E-MTAB-9468 | biostudies-arrayexpress

Differential expression genes between PC9 cells and osimertinib resistant PC9OR cells

Project description:To investigate the possible resistant mechanism to osimertinib, PC9 cells and their derived osimertinib-resistant PC9OR cells were sequenced using illumina HiSeq. We then performed gene expression profiling analysis using data obtained from RNA-seq of PC9 cells and their derived PC9OR cells.

2022-11-02 | GSE201549 | GEO

Study on differentially expressed genes in the WT1 overexpressed group and the control group by RNA-seq

Project description:Study on differentially expressed genes in the WT1 overexpressed group and the control group by RNA-seq

| PRJNA598831 | ENA

Study on differentially expressed genes in the WT1 overexpressed group and the control group by RNA-seq

Project description:Purpose: The aim was to find the differentially expressed genes between the WT1 overexpressed group and the control group Methods:Hacat cell was transfected with WT1 overexpressed plasmids and blank plasmids, then RNA from both groups of cells was sequenced. The data obtained from the sequencing is called raw reads, and then the raw reads are subject to quality control QC. After the quality control is passed, the filtered clean reads are compared to the reference genome, This was followed by gene Quantitative analysis, gene expression level based analyses, and more in depth mining analyses such as GO functional significance enrichment analysis and pathway significance enrichment analysis for the selected differentially expressed genes between samples. Conclusions:Our study was the first to analyze the transcriptome of Hacat cells overexpressing WT1 generated by RNA-seq technique and to conduct biological replication. Six samples were measured using BGISEQ-500 platform, and the average output of each sample was 21.89 m. The average ratio of sample to genome was 94.81% . A total of 17,693 genes were detected. A total of 181 differentially expressed genes between the two groups were analyzed by GO and Kegg.

2023-01-03 | GSE142985 | GEO

Expression data of osimertinib tolerant H1975 cells

Project description:Even after osimertinib is administered to lung adenocarcinomas with EGFR mutations, there are a few cells which survive, and these tolerant cells are considered to be the source of later recurrence. We used microarray analysis to explore the mechanism behind the tolerance to osimertinib in lung adenocarcinoma cells with EGFR mutations.

2022-04-16 | GSE200893 | GEO

3' UTR RNA-sequencing of humanized EGFR-mutant PC9 cell line xenografts treated with osimertinib/vehicle of RIG-I agonist IVT4/unspecific control IVT-GAC

Project description:Immunocompromised mice were inoculated with human lung adenocarcinoma cell line PC9 and with human PBMCs. Tumors were treated with osimertinib/vehicle of RIG-I agonist IVT4/unspecific control IVT-GAC to assess response.

2021-07-20 | E-MTAB-9891 | biostudies-arrayexpress

Expression data of osimertinib tolerant PC-9 cells

2022-04-16 | GSE200894 | GEO

Osimertinib resistant cells of H1975

Project description:To tentatively explored the latent roles of miRNAs in Osimertinib treatment response and tried to explore the methylation related miRNA maturation in the generation of resistance

2021-09-30 | GSE184980 | GEO

A Novel Molecular Target in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer treated with a Combination of Osimertinib and Pemetrexed

Project description:In this study, we evaluate the therapeutic potential of combining osimertinib with pemetrexed and clarify the underlying molecular mechanisms in order to establish novel therapeutic strategies for EGFR-mutant NSCLC. We found that the combination of osimertinib and pemetrexed could induce strong apoptotic activity and enhance anti-tumor effects compared to monotherapy in two NSCLC cell lines harboring an EGFR mutation. In addition, we have identified PLK1 as a therapeutic target for combination therapy and as a promising treatment target for overcoming resistance to osimertinib in EGFR-mutated NSCLC patients.

2021-10-14 | GSE165029 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data